| 唐慕菲,张保国,沈芸竹,等.替雷利珠单抗药物利用评价标准的建立与应用[J].安徽医药,2025,29(1):196-199. |
| 替雷利珠单抗药物利用评价标准的建立与应用 |
| Establishment and application of evaluation criteria for drug use evaluation of tislelizumab |
| |
| DOI：10.3969/j.issn.1009-6469.2025.01.040 |
| 中文关键词: 药物利用评价 替雷利珠单抗 评价标准 合理用药 住院病人 |
| 英文关键词: Drug use evaluation Tislelizumab Evaluation criteria Rational use of drugs Hospitalized patient |
| 基金项目:江苏省药学会 -正大天晴医院药学科研项目( Q202214) |
|
| 摘要点击次数: 438 |
| 全文下载次数: 235 |
| 中文摘要: |
| 目的针对替雷利珠单抗建立药物利用评价( drug use evaluation，DUE)标准，对南京医科大学附属南京医院替雷利珠单抗使用情况进行评价，为临床合理用药提供参考依据。方法根据替雷利单抗药品说明书、临床相关指导原则、诊疗指南和专家共识等，建立替雷利珠单抗 DUE标准，依据标准回顾性分析评价 2023年 1—9月南京医科大学附属南京医院使用替雷利珠单抗的住院病人用药情况。结果替雷利珠单抗 DUE标准包含 14个指标。纳入 96例病人，共使用替雷利珠单抗 687次。体力评分、器官功能和实验室指标、给药剂量、给药途径、输注时间、给药频次和疗效评估合理率 100%；禁忌证、溶媒种类和用量合理率 98.96%；联合用药合理率 97.92%；药物相互作用合理率 96.88%；给药顺序和时间合理率 84.38%；适应证合理率 80.21%；不良反应监测与处理合理率 39.58%。结论建立并应用替雷利珠单抗 DUE标准可发现用药过程中的不合理现象，为临床安全用药提供参考依据。 |
| 英文摘要: |
| Objective To establish a drug use evaluation (DUE) standard for the use of tislelizumab in Nanjing First Hospital, Nan-jing Medical University, and to evaluate the use of tislelizumab in order to provide a reference basis for rational clinical medication.Methods Based on the drug instructions, clinical guidelines for tumor diagnosis and treatment, and expert consensus, as well as theclinical application guidelines for new anti-tumor drugs, a DUE standard for tislelizumab was established. Based on the standard, a ret-rospective analysis was conducted to evaluate the medication use of tislelizumab in hospitalized patients from January 2023 to Septem-ber 2023.Results The DUE standard for tislelizumab included 14 indicators. A total of 96 patients were included and a total of 687doses of tislelizumab were used. The reasonable rate of physical fitness score, organ function and laboratory indicators, dosage, route ofadministration, infusion time, frequency of administration, and efficacy evaluation was 100%; The reasonable rate of contraindications,types of solvents, and dosage was 98.96%; The reasonable rate of combination therapy was 97.92%; The reasonable rate of drug interac-tion was 96.88%; The reasonable rate of administration sequence and time was 84.38%; The reasonable rate of indications was 80.21%;The reasonable rate of adverse reaction monitoring and treatment was 39.58%.Conclusion Establishing and applying the DUE stan-dard for tislelizumab can detect unreasonable phenomena during the medication process and provide reference for safe clinical use. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
